ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biotechnology company, announced today that the Company has filed for Breakthrough Therapy designation ...
Comprehensive profiling of cancer associated cells in the blood of breast cancer patients to predict pathological complete response. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting ...
Bristol-Myers Squibb Company BMY announced that the European Commission (“EC”) has approved its CD19-directed CAR-T cell therapy, Breyanzi (lisocabtagene maraleucel), for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results